Summary of Whitehawk Therapeutics Conference Call Company Overview - **Company Name**: Whitehawk Therapeutics (formerly Adi Biosciences) [4] - **CEO**: Dave Lennon [2] - **Focus**: Advanced Antibody-Drug Conjugates (ADCs) targeting various cancers [2][4] Key Developments - **Strategic Transactions**: - In-licensed three ADCs from Ushia Biologics [4] - Divested Fiaro to Kaken Pharmaceuticals [4] - Completed a $100 million PIPE financing [4] - **Transition to Whitehawk**: The company relaunched as Whitehawk Therapeutics in March 2025, focusing on ADC therapeutics [4][5] ADC Portfolio - **Portfolio Composition**: Three ADC assets targeting validated tumor markers: PTK7, MUC16, and SCC6 [8][9] - **Clinical Strategy**: - All three INDs (Investigational New Drug applications) expected to be filed by mid-2026 [7][17] - Cash reserves of approximately $185 million to fund operations into 2028 [7] Targeted Tumor Markers 1. **PTK7**: - Overexpressed in various tumors, particularly in non-small cell lung cancer and gynecological cancers [9][18] - No approved ADCs targeting PTK7 currently exist [9] - Expected to have a significant patient population, with 60-70% of patients expressing PTK7 during their cancer journey [18] 2. **MUC16**: - Targets a glycoprotein overexpressed in female-origin tumors, including ovarian cancer [10][21] - Previous studies by Genentech showed high response rates but required high doses due to the antigen sink effect [21][22] - Whitehawk's approach targets the membrane-bound portion to avoid this effect [22] 3. **SCC6**: - Targets a CNS-limited protein overexpressed in neuroendocrine tumors, particularly small cell lung cancer [11][24] - Whitehawk plans to utilize a biparatopic approach to enhance efficacy and safety [25] Technology Platform - **CPT113**: Advanced ADC technology platform with a proprietary TOPO-one inhibitor payload and stable linker chemistry [12][13] - **Advantages**: - Improved stability and reduced off-target toxicity compared to first-generation ADCs [13][14] - Expected efficacy gains of 15-30% over existing therapies [16] Market Potential - **Expansion Opportunities**: Significant unmet needs in targeted cancers, with potential for expansion into various indications [17][18] - **Competitive Landscape**: Acknowledgment of competition from other ADCs, particularly from AbbVie, but with a focus on improving safety and efficacy profiles [34] Financial Outlook - **Cash Runway**: Sufficient funds to support operations and clinical trials through early 2028 [27][41] - **Future Funding**: No plans to raise additional funds until clarity on the portfolio's next steps is achieved [43] Conclusion - Whitehawk Therapeutics is positioned to leverage its advanced ADC technology and validated tumor targets to address significant unmet needs in cancer treatment, with a well-capitalized structure to support its clinical development plans [26][27]